MetaVia to Present New Phase 1 and Pre-Clinical Data on DA-1726 at ObesityWeek® 2025

Core Insights - MetaVia Inc. announced new Phase 1 and pre-clinical data for DA-1726, a dual oxyntomodulin analog, showing favorable safety, tolerability, and clinically meaningful weight loss without dose titration [1][2][12] - The Phase 1 trial demonstrated a significant body weight reduction of up to 6.3% from baseline and a waist circumference decrease of up to 3.9 inches after four weeks of treatment [2][4] - DA-1726 exhibited superior lipid-lowering effects compared to pemvidutide in pre-clinical models, indicating its potential as a differentiated treatment for obesity [7][9] Phase 1 Trial Results - The Phase 1 trial was randomized, double-blind, and placebo-controlled, assessing safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) in obese adults with a BMI of 30–45 kg/m² [4] - At the highest tested dose of 32 mg, participants experienced an average weight reduction of 4.3% at Day 26, with effects sustained for two weeks post-treatment [2][3] - DA-1726 demonstrated a mean half-life of approximately 80 hours, supporting once-weekly dosing [3][12] Pre-clinical Data Insights - In pre-clinical studies, DA-1726 showed comparable weight loss to pemvidutide while achieving greater reductions in total cholesterol and LDL-C [7][9] - The drug promoted weight reduction by suppressing appetite and increasing energy expenditure without increased physical activity [8][12] - DA-1726's metabolic profile suggests broader and more durable benefits for patients with obesity compared to other dual agonists [7][9] Future Directions - MetaVia has extended the Phase 1 study to evaluate a 48 mg dose over eight weeks to assess longer-term efficacy and patient exposure [2][4] - Results from the extended cohort are expected later this year, which may provide further insights into DA-1726's potential as a treatment for obesity [2][4]